CS99, ... I thank you for your response.
So if I understand you correctly, to dampen the cytokine storm, that needs drugs. So that drug potentially can be Apabetalone if proven to be effective. So if a COVID 19 patient is not helped with the likes of Apabetone to dampen the cytokine storm, the patient is then put on mechanical ventilation or extracorporeal membrane oxygenation, as the patient is beyond help from anti-viral anti-inflammation drugs like Apabetalone, + standard of care meds. Is this the right order of things in dealing with a COVID 19 patient inside an ICU?
All I'm trying to figure out is why "Subjects requiring mechanical ventilation or extracorporeal membrane oxygenation", are excluded from the open-label study of Apabetalone in Covid-19 infection clinical trial NCT04894266.
Koo